Is It Worth Investing in Lam Research (LRCX) Based on Wall Street's Bullish Views?
Werte in diesem Artikel
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Lam Research (LRCX) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Lam Research currently has an average brokerage recommendation (ABR) of 1.61, on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 31 brokerage firms. An ABR of 1.61 approximates between Strong Buy and Buy.Of the 31 recommendations that derive the current ABR, 20 are Strong Buy and three are Buy. Strong Buy and Buy respectively account for 64.5% and 9.7% of all recommendations.Brokerage Recommendation Trends for LRCXCheck price target & stock forecast for Lam Research here>>>The ABR suggests buying Lam Research, but making an investment decision solely on the basis of this information might not be a good idea. According to several studies, brokerage recommendations have little to no success guiding investors to choose stocks with the most potential for price appreciation.Are you wondering why? The vested interest of brokerage firms in a stock they cover often results in a strong positive bias of their analysts in rating it. Our research shows that for every "Strong Sell" recommendation, brokerage firms assign five "Strong Buy" recommendations.This means that the interests of these institutions are not always aligned with those of retail investors, giving little insight into the direction of a stock's future price movement. It would therefore be best to use this information to validate your own analysis or a tool that has proven to be highly effective at predicting stock price movements.With an impressive externally audited track record, our proprietary stock rating tool, the Zacks Rank, which classifies stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), is a reliable indicator of a stock's near-term price performance. So, validating the Zacks Rank with ABR could go a long way in making a profitable investment decision.ABR Should Not Be Confused With Zacks RankIn spite of the fact that Zacks Rank and ABR both appear on a scale from 1 to 5, they are two completely different measures.Broker recommendations are the sole basis for calculating the ABR, which is typically displayed in decimals (such as 1.28). The Zacks Rank, on the other hand, is a quantitative model designed to harness the power of earnings estimate revisions. It is displayed in whole numbers -- 1 to 5.It has been and continues to be the case that analysts employed by brokerage firms are overly optimistic with their recommendations. Because of their employers' vested interests, these analysts issue more favorable ratings than their research would support, misguiding investors far more often than helping them.In contrast, the Zacks Rank is driven by earnings estimate revisions. And near-term stock price movements are strongly correlated with trends in earnings estimate revisions, according to empirical research.In addition, the different Zacks Rank grades are applied proportionately to all stocks for which brokerage analysts provide current-year earnings estimates. In other words, this tool always maintains a balance among its five ranks.Another key difference between the ABR and Zacks Rank is freshness. The ABR is not necessarily up-to-date when you look at it. But, since brokerage analysts keep revising their earnings estimates to account for a company's changing business trends, and their actions get reflected in the Zacks Rank quickly enough, it is always timely in indicating future price movements.Is LRCX a Good Investment?In terms of earnings estimate revisions for Lam Research, the Zacks Consensus Estimate for the current year has increased 0.3% over the past month to $4.Analysts' growing optimism over the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher, could be a legitimate reason for the stock to soar in the near term.The size of the recent change in the consensus estimate, along with three other factors related to earnings estimates, has resulted in a Zacks Rank #2 (Buy) for Lam Research. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>Therefore, the Buy-equivalent ABR for Lam Research may serve as a useful guide for investors.Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Lam Research Corporation (LRCX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: Lam Research und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Bullish
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Bullish
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Lam Research Corp.
Analysen zu Lam Research Corp.
Datum | Rating | Analyst | |
---|---|---|---|
25.04.2019 | Lam Research Outperform | Cowen and Company, LLC | |
22.04.2019 | Lam Research Buy | B. Riley FBR | |
24.01.2019 | Lam Research Outperform | Cowen and Company, LLC | |
21.12.2018 | Lam Research Buy | Needham & Company, LLC | |
29.10.2018 | Lam Research Neutral | B. Riley FBR |
Datum | Rating | Analyst | |
---|---|---|---|
25.04.2019 | Lam Research Outperform | Cowen and Company, LLC | |
22.04.2019 | Lam Research Buy | B. Riley FBR | |
24.01.2019 | Lam Research Outperform | Cowen and Company, LLC | |
21.12.2018 | Lam Research Buy | Needham & Company, LLC | |
17.10.2018 | Lam Research Outperform | Cowen and Company, LLC |
Datum | Rating | Analyst | |
---|---|---|---|
29.10.2018 | Lam Research Neutral | B. Riley FBR | |
01.10.2018 | Lam Research Hold | Deutsche Bank AG | |
01.10.2018 | Lam Research Neutral | Mizuho | |
12.10.2016 | Lam Research Sector Weight | Pacific Crest Securities Inc. | |
21.04.2015 | Lam Research Sector Perform | RBC Capital Markets |
Datum | Rating | Analyst | |
---|---|---|---|
22.10.2015 | Lam Research Underperform | RBC Capital Markets | |
05.10.2015 | Lam Research Underperform | RBC Capital Markets | |
11.11.2010 | Lam Research sell | Citigroup Corp. | |
29.07.2010 | Lam Research sell | Citigroup Corp. | |
19.03.2009 | Lam Research underperform | Credit Suisse Group |
Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Lam Research Corp. nach folgenden Kriterien zu filtern.
Alle: Alle Empfehlungen